A group of Chilean investors has acquired Farmacias Ahumada
A group of Chilean investors has acquired Farmacias Ahumada S.A. from Walgreens Boots Alliance.
The acquisition is carried out by a selected group of non-institutional chilean investors.
Founded in 1968, Farmacias Ahumada operates as one of the three main pharmaceutical chains in Chile, with almost 300 drugstores. It offers a range of products and services, such as drugs, natural products, nutritional supplements and beauty items and personal care products. The company is based in Santiago.
Walgreens Boots Alliance is an American public multinational holding headquartered in Illinois. It is an integrated healthcare, pharmacy and retail leader, which owns the pharmacy chains Walgreens in the US and Boots in the UK and internationally, as well as the Benavides brand in Mexico.
Oaklins’ team in Chile advised a group of Chilean investors on the acquisition of Farmacias Ahumada.
Prata med transaktionsteamet
Relaterade transaktioner
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Lär dig merbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Lär dig merBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Lär dig mer